201.21
-1.82 (-0.90%)
| Penutupan Terdahulu | 203.03 |
| Buka | 199.08 |
| Jumlah Dagangan | 156,409 |
| Purata Dagangan (3B) | 322,640 |
| Modal Pasaran | 5,823,617,024 |
| Harga / Pendapatan (P/E TTM) | 30.21 |
| Harga / Pendapatan (P/E Ke hadapan) | 29.33 |
| Harga / Jualan (P/S) | 17.40 |
| Harga / Buku (P/B) | 5.54 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 3 Nov 2025 |
| Margin Keuntungan | 37.17% |
| Margin Operasi (TTM) | 41.03% |
| EPS Cair (TTM) | 4.18 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 94.90% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 3,734.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.98% |
| Nisbah Semasa (MRQ) | 9.65 |
| Aliran Tunai Operasi (OCF TTM) | 138.50 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 76.74 M |
| Pulangan Atas Aset (ROA TTM) | 8.66% |
| Pulangan Atas Ekuiti (ROE TTM) | 13.90% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Krystal Biotech, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.63 |
|
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 11.88% |
| % Dimiliki oleh Institusi | 104.04% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 255.00 (B of A Securities, 26.73%) | Beli |
| Median | 230.00 (14.31%) | |
| Rendah | 198.00 (Citigroup, -1.60%) | Pegang |
| Purata | 228.25 (13.44%) | |
| Jumlah | 3 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 188.12 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Chardan Capital | 04 Nov 2025 | 220.00 (9.34%) | Beli | 203.26 |
| Citigroup | 04 Nov 2025 | 198.00 (-1.60%) | Pegang | 203.26 |
| B of A Securities | 17 Oct 2025 | 255.00 (26.73%) | Beli | 190.23 |
| HC Wainwright & Co. | 15 Sep 2025 | 240.00 (19.28%) | Beli | 155.71 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 26 Nov 2025 | Pengumuman | Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference |
| 03 Nov 2025 | Pengumuman | Krystal Biotech Announces Third Quarter 2025 Financial and Operating Results |
| 21 Oct 2025 | Pengumuman | Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025 |
| 14 Oct 2025 | Pengumuman | Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis |
| 15 Sep 2025 | Pengumuman | Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |